The LMO2 gene is involved in T-cell acute leukaemia (T-ALL) in children with chromosomal translocations t(11;14)(p13;q11) or (7;11)(q35;p13). Transgenic expression of Lmo2 in T cells results in clonal tumours with long latency indicating that mutations in other genes are required for the development of overt tumours. RAG V-D-J recombinase can mediate genetic transposition and thus might create the secondary mutations necessary for T-ALL. Tumour development was compared in Lmo2 transgenic mice in the presence or absence of the Rag1 gene. No dierence was observed in the rate of tumour formation nor in tumour histology in Lmo2-transgenic mice with or without Rag1. We conclude that, in this model, RAG recombinase is not a major mediator of mutations needed for T cell tumorigenesis and that antigen binding (1994)). The LIM-only genes LMO1 and LMO2 were discovered by their activation through the T cell-speci®c translocations t(11;14)(p15;q11) and t(11;14)(p13;q11) respectively (Rabbitts, 1998) (LMO2 is also activated by a variant translocation t(7;11)(q35;p13) in a subset of T-ALL (Sanchez-Garcia et al., 1991) . Mouse models of T-ALL mediated by Lmo1 or Lmo2 demonstrate that transgenic mice expressing these genes develop clonal T cell tumours after several months (Aplan et al
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Keywords: chromosomal translocation; leukaemia; T cells; T-ALL Human T-cell acute leukaemias (T-ALL) are characterized by one of a number of dierent reciprocal chromosomal translocations (reviewed in Rabbitts (1994) ). The LIM-only genes LMO1 and LMO2 were discovered by their activation through the T cell-speci®c translocations t(11;14)(p15;q11) and t(11;14)(p13;q11) respectively (Rabbitts, 1998) (LMO2 is also activated by a variant translocation t(7;11)(q35;p13) in a subset of T-ALL (Sanchez-Garcia et al., 1991) . Mouse models of T-ALL mediated by Lmo1 or Lmo2 demonstrate that transgenic mice expressing these genes develop clonal T cell tumours after several months (Aplan et al., 1997; Fisch et al., 1992; Larson et al., 1994 Larson et al., , 1995 Larson et al., , 1996 McGuire et al., 1992; Neale et al., 1995) . In addition, a pre-leukaemic eect of Lmo2 transgene expression is the accumulation of immature T cells lacking CD4 and CD8 surface molecule expression (designated DN cells) (Larson et al., 1995 (Larson et al., , 1996 Neale et al., 1995 Neale et al., , 1997 . This suggests that this population of DN cells is the precursor of cells which develop secondary mutations in other genes (as yet undetermined) leading to overt T cell tumours (Larson et al., 1995; Neale et al., 1997; Rabbitts, 1998) . The Lmo2-transgene eect on DN T cell dierentiation was exacerbated by generating double transgenic lines expressing both Lmo2 and Tal1/Scl in T cells (Larson et al., 1996) . Tal1 is a protein binding partner of Lmo2 (Larson et al., 1996; Valge-Archer et al., 1994; Wadman et al., 1994 Wadman et al., , 1997 suggesting that protein ± protein interaction plays a key role in T-ALL (Rabbitts, 1998) . Similar eects of Lmo1 and Tal1 transgenes on T cell development have been described (Chervinsky et al., 1999; Herblot et al., 2000) .
In both models, tumour development is slow and clonal tumours occur, indicating that the transgene is necessary but not sucient for tumour formation and that other genetic changes are needed for tumorigenesis. The process by which these changes occur remains a mystery. Mutations may occur randomly and are additive until the full tumour phenotype is manifest, or a positive mutational process may operate in the preleukaemic cells, facilitating the necessary mutations. In this model, an intriguing possibility arises from the observation that the RAG V-D-J recombinase can mediate transpositions as well as intra-chromosomal rearrangements (Agrawal et al., 1998; Hiom et al., 1998) , namely that recombinase could facilitate mutations. Furthermore, examination of the pre-leukaemic cells in the Lmo2-transgenic mice showed an enhanced number of DN T cells (Larson et al., 1995; Rabbitts, 1998) , which is the population where Rag proteins are active (Fischer and Malissen, 1998) .
The hypothesis that Rag-mediated events are responsible for secondary mutations in Lmo2-transgenic T cell tumours was tested by comparing tumorigenesis in these mice in the presence or absence of the Rag1 gene. CD2-lmo2 (previously called CD2-rbtn2 (Fisch et al., 1992) ) transgenic mice were bred with Rag1 de®cient mice (Spanopoulou et al., 1994) to generate two groups of CD2-lmo2 transgenics which were either homozygous null Rag1 or wild-type Rag1. The CD2-lmo2 transgene was designed to induce sustained Lmo2 expression in the T cell lineage under the control of the CD2 promoter and enhancer (Lake et al., 1990; Lang et al., 1988) whilst the Rag1 null mice fail to make mature lymphocytes due to lack of antigen-receptor gene rearrangement (Mombaerts et al., 1992; Shinkai et al., 1992; Spanopoulou et al., 1994) . Thus a mouse with the CD2-lmo2 transgene accompanied by the Rag1 null mutation can only produce immature T cells, up to the CD447/low, CD25+ stage (Malissen et al., 1984) .
The cohorts of CD2-lmo2; Rag1 mutant mice produced for our study were kept under surveillance for signs of tumour development for 14 months (i.e. was the period in which T cell tumour development has previously been observed (Fisch et al., 1992; Larson et al., 1994) ). When animals displayed signs of illness, they were sacri®ced and a post-mortem examination was performed. In all cases, thymus, spleen and liver samples were removed for histological analysis. Mice in both groups developed thymomas. The proportion of mice in each group which developed disease in the 14 month experimental period was approximately the same (82% for CD2-lmo2; Rag17/7 and 72% for CD2-lmo2; Rag1+/+). This is within the range of incidence previously observed (Fisch et al., 1992; Larson et al., 1994) and indicates that the absence of the Rag1 gene per se is not deleterious to T cell tumour development. In addition, the tumour incidence curves (Figure 1 ) do not display any signi®cant dierences between the groups. The approximate time at which half of the tumours had arisen was about 9 months.
Post-mortem examination of all mice revealed that those with tumours had enlarged thymus (thymoma), increased spleen volume, pale liver with white nodules and pale kidney. Histology of the spleen showed loss of distinction of white and red pulp (Figure 2 ) due to the homogenous presence of malignant lymphocytes. Tumour cells also ®lled the thymus. The livers of tumour-bearing mice showed characteristic peri-vascular deposits of malignant lymphocytes (Figure 2 ) which also in®ltrated into larger deposits or nodules on the outside of the organ. The pathology of the disease showed no dierences between mice with the dierent Rag1 gene status. We conclude that thymoma development in CD2-lmo2 transgenic mice is independent of Rag1 gene activity and therefore that the RAG V-D-J recombinase does not play a part in tumorigenesis in this model.
The pathogenic phenotype of T cell tumours in CD2-lmo2 transgenic mice ®rst appears as an eect on T cell dierentiation whereby CD4, CD8 DN cells accumulate during the ®rst few months, followed by overt T cell tumours arising from about 5 months onwards (Fisch et al., 1992; Larson et al., 1994) . The DN T cell population is normally where the Rag genes are expressed (Fischer and Malissen, 1998) . The absence of the Rag1 protein in Rag17/7 mice blocks T cell development at the DN, CD25+, CD447 T cell precursor stage (Fischer and Malissen, 1998 ). This does not eect the development of thymomas in our Lmo2-dependent tumour model, therefore putative secondary mutations cannot be mediated by the RAG V-D-J recombinase. In addition, since the Rag17/7 mice cannot rearrange T cell receptor genes and thus never express surface T cell receptor, antigen engagement of this receptor is not needed for tumorigenesis in these transgenic mice.
In previous studies of Lmo2 transgenic mice, we have observed tumours arising in CD47, CD87, CD25+, CD44+ T cell precursors and in CD47, CD87, CD25+, CD447 cells (Grutz et al., 1998; Larson et al., 1995) . These cells usually express the Rag genes and TCRb rearrangement occurs in these cells (Fischer and Malissen, 1998) . Thus in CD2-lmo2 transgenics, there is a co-incident emergence of T cell tumours and the expression of Rag recombinase. These observations are consistent with our previous model for the origin of chromosomal translocations in human T-ALL (Rabbitts, 1998 (Rabbitts, , 1999 , which is based on the fact that T-ALL chromosomal translocation breakpoints appear to be recombinase-mediated as judged by sequence analysis of the breakpoints (Finger et al., 1986; Sanchez-Garcia et al., 1991) . We propose that the chromosomal translocation event occurs in the RAGexpressing immature T cell precursors in humans which are analogous to the CD47, CD87, CD25+, CD44+/7 cells in the transgenic model. The chromo- Figure 1 Thymoma incidence in CD2-Lmo2 transgenic mice with or without the Rag1 gene. CD2-lmo2 transgenic mice (Fisch et al., 1992) were bred with Rag1 null mice (Spanopoulou et al., 1994) to generate transgenic mice with two dierent Rag1 genotypes, Rag1+/+ and Rag17/7. Genotypes of the ospring were determined by ®lter hybridization of genomic DNA as described (LeFranc et al., 1986) . Genomic DNA was digested with HindIII (CD2-lmo2) or BamHI (Rag) and hybridized respectively with pMR2A12N or pTEXCD2 (Lang et al., 1988) and a 3.4 Kb Rag1 genomic XhoI fragment (A Forster and THR (2001) , unpublished) DNA probes. Cohorts of mice were generated (CD2-lmo2; Rag1+/+, n=31; CD2-lmo2; Rag17/7, n=30) and maintained in a pathogen-free facility. The health status of the mice was monitored and mice showing signs of ill-health (reduction of food and water intake, rued fur, compromised mobility and/or hunched posture) were sacri®ced and a post-mortem examination conducted. The criteria for scoring a mouse with a T cell tumour was the presence of enlarged spleen, thymus, lymph nodes, pale and spotty liver and kidney. Organs were removed from those mice with these features and histology carried out (see Figure 2) . The graphs show the proportion of mice with thymomas in the two categories of CD2-lmo2 transgenic mice plotted against time in months. The approximate 50% point for each group is taken from the curves as shown by the dashed lines. Small discrepancies in the incidence are not statistically signi®cant and are attributable to the way in which tumour timing had to be assessed (i.e. the ®rst outward appearance of any distress in an individual mouse somal translocation creates the pre-leukaemic state but overt disease requires other genetic mutations to act in concert with the eect of the chromosomal translocation. This is a comprehensive model of T-ALL initiated by chromosomal translocation. The outstanding issues are the mechanism and nature of the secondary mutations and the precise delineation of the protein interactions which are mediated by the enforced Lmo2 expression following the chromosomal translocation. The interaction of Lmo2 with the Ldb1 molecule is likely to be a key molecular event in Lmo2-mediated T-ALL (Rabbitts, 1998; Valge-Archer et al., 1998) . Figure 2 Histological comparison of T cell tumours arising in CD2-Lmo2 transgenic mice with or without the Ragl gene. Organs were removed from control or tumour-bearing mice, ®xed in 10% formalin for at least 60 h, wax embedded and 50 mM sections made. These were stained with haematoxylin and eosin prior to photography. Sections of spleen, thymus and liver are shown for specimen examples of wild-type (wt), CD2-lmo2; Rag1+/+ (Rag +/+) and CD2-lmo2; Rag17/7(Rag 7/7) mice. The ages were 14 months, 8 months and 10 months respectively. Magni®cation640
